Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors.

Background: Immune checkpoint inhibitors (ICIs) have limited response rates in selected patients and can cause potentially life-threatening immune-related adverse events (irAEs). This underscores the urgent need for the development of biomarkers predictive of ICI response. Pre-existing autoantibodies (AAbs) have been linked with responses to ICIs and the development of irAEs.

Role and mechanism of piR-0228 targeting RIPK1 to regulate vascular remodeling and aortic dissection.

The diagnosis and management of aortic dissection (AD), a critical cardiovascular disease (CVD), remains significant challenges in clinical practice. PIWI-interacting RNAs (piRNAs), a newly discovered class of non-coding small RNAs, play key regulatory role in various CVDs. However, the mechanism of their action in AD remains unclear.

IGF-1R inhibitors in cancer: A review of available evidence and future outlook.

The insulin-like growth factor-1 receptor (IGF-1R) has emerged as a critical target in oncology due to its pivotal role in tumor growth, progression, and therapeutic resistance. Despite encouraging preclinical findings, clinical trials utilizing IGF-1R inhibitors as monotherapies have largely been unsuccessful. Herein, we reviewed the available data with IGF-1R inhibitors and the potential of IGF-1R inhibitors when used in combination therapies, an approach supported by advances in precision medicine and immuno-oncology.

Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial.

Introduction: Rare solid tumors account for one-quarter of cancers among adults in the United States, but few resources have been devoted to their treatment. We evaluated the efficacy of pembrolizumab, a programmed cell death-1 inhibitor, in patients with rare solid tumors.

Methods: We conducted a phase 2 basket trial that included patients with rare, advanced tumors.